Pembrolizumab is approved for use in several types of cancer, including certain blood cancers. For blood cancers, it is specifically indicated for:

Adults with relapsed or refractory classical Hodgkin lymphoma (cHL)
Pediatric patients with refractory cHL, or cHL that has relapsed after two or more lines of therapy
Adults and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy

While pembrolizumab is not specifically approved for Anaplastic Large Cell Lymphoma (ALCL), it may be considered in certain cases if other treatments are not suitable, but this would be at the discretion of your cancer care team. Always discuss your specific diagnosis and treatment options with your healthcare provider.

Pembrolizumab (Keytruda)

Common brand names

Approved use in

Administration method